SynthesisPloS one2014
Factors predicting malignancy in patients with polymyositis and dermatomyostis: a systematic review and meta-analysis.
Synthesis in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 142 citations in OpenAlex.
- Article
- Periorbital heliotrope erythema with edema as a potential clinical marker of paraneoplastic Dermatomyositis - a case series.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026Review
- Idiopathic inflammatory myopathies: a comprehensive review, new concepts on diagnostic imaging and whole-body MRI.European radiology · 2026Review
- Clinical Characteristics and Malignancy Prevalence in Idiopathic Inflammatory Myopathies: A Single-Center Study from Southwestern Saudi Arabia.Open access rheumatology : research and reviews · 2026Article
- Atypical Interplay of Dermatomyositis, Metastatic Caecal Carcinoma, and Connective Tissue Disease.Cureus · 2026Article
- Case Report: breast cancer presenting as dermatomyositis.Frontiers in oncology · 2026Article
- A five-factor risk-stratification model for cancer-associated myositis in idiopathic inflammatory myopathies and stage-specific survival analysis: a multicentre Japanese MYKO cohort study.Frontiers in immunology · 2026Article
- MICA protein as a plasma biomarker for dermatomyositis with malignancy: a proteome-wide Mendelian randomization and ELISA study.Clinical rheumatology · 2026Article
- Malignancy in Idiopathic Inflammatory Myopathies: Recent Insights.Clinical reviews in allergy & immunology · 2025Review
- Review
- Paraneoplastic Amyopathic Dermatomyositis Associated With a Bone and Medullary Location of Breast Adenocarcinoma.Cureus · 2025Article
- Spatial Transcriptomics Identifies Immune-Stromal Niches Associated with Cancer in Adult Dermatomyositis.bioRxiv : the preprint server for biology · 2025Article
- Article
- Cancer in connective tissue disease.Frontiers in immunology · 2025Review
- Risk, risk factors, and screening of malignancies in dermatomyositis: current status and future perspectives.Frontiers in oncology · 2025Review
- Small cell lung cancer with dermatomyositis: a case report.Frontiers in oncology · 2024Article
- Dermatomyositis unleashed by immune checkpoint inhibitors. Three additional cases and a review of the literature.Autoimmunity reviews · 2023Review
- Association of Anti-CCAR1 Autoantibodies With Decreased Cancer Risk Relative to the General Population in Patients With Anti-Transcriptional Intermediary Factor 1γ-Positive Dermatomyositis.Arthritis & rheumatology (Hoboken, N.J.) · 2023Article
- Clinical Characteristics of Dermatomyositis with Interstitial Lung Disease: A Retrospective Case-Control Study.Rheumatology and therapy · 2023Article
- [Dermatomyositis and juvenile dermatomyositis].Zeitschrift fur Rheumatologie · 2023Review
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo define potential factors that could predict concomitant neoplastic diseases in patients diagnosed with PM/DM, which could inform screening decisions.
methodsTwo researchers independently reviewed articles from Pubmed (MEDLINE), EMBASE, Cochrane Plus Library and ISI Web of Knowledge with no restrictions on study design or language. Given that some of the studies combined PM and DM patients as research subjects while others included only DM patients, data were subjected to meta-analyses for all combined PM/DM studies and studies that included only DM patients to obtain informative results.
resultsFor PM/DM patients, the following factors are all associated with an increased risk of malignancy: older age, age greater than 45, male sex, dysphagia, cutaneous necrosis, cutaneous vasculitis, rapid onset of myostis (<4 weeks), elevated CK, higher ESR, higher CRP levels. Several factors were associated with lower-than-average risk, including the presence of ILD, arthritis/arthralgia, Raynaud's syndrome, or anti-Jo-1 antibody. For DM patients, results indicated an increased risk of malignancy with older age, male sex, the presence of cutaneous necrosis, elevated ESR (>35 mm/hr), higher CRP levels, or anti-p155 antibody. In addition, the presence of anti-ENA antibodies seem to be related to reduced risk of malignancy.
conclusionAwareness and implementation of early-stage cancer screening in PM/DM patients who have these identified factors--such as being older than 45, male sex, cutaneous necrosis, cutaneous vasculitis--are of crucial importance from public health and clinical perspectives and provide insight into the etiopathogenesis of CAM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.